

## Meeting Agenda

<b>Group: ISPOR 47th HTA Roundtable – Asia Pacific</b>			
<b>Date:</b> Friday October 25, 2019		<b>Time:</b> 8:00AM-12:00PM	
<b>Meeting Location:</b> Rome Ballroom, Marco Polo Parkside Beijing, Beijing, China			
<b>Invitees:</b> Refer to the attendee list			
Item #	Time	Topic	Presenter(s)
1.	8:00-8:15	<b>Welcome &amp; Introduction</b> <ul style="list-style-type: none"> <li>➤ Welcome from Roundtable Co-Chairs</li> <li>➤ Welcome from ISPOR</li> <li>➤ ISPOR Anti-Trust Statement</li> <li>➤ Delegate Introduction</li> </ul>	Churn-Shiouh Gau Sukyeong Kim Nancy Devlin Robert Selby All Delegates
2.	8:15-9:00 8:15-8:30 8:30-8:45 8:45-9:00	<b>Presentation Session I: High-Cost Drugs and Curative Therapies</b> <ul style="list-style-type: none"> <li>➤ Uncertainty and Managed Access Programs – Australia</li> <li>➤ Drug Negotiation and Pricing – China Case</li> <li>➤ Risk Sharing Arrangements in Korea – HIRA’s Experience</li> </ul>	Churn-Shiouh Gau Kirsten Howard Jing Wu Yoon Hee Choi
3.	9:00-9:45	<b>Discussion Session I</b>	Churn-Shiouh Gau
4.	9:45-10:00	<b>Coffee / Tea Break</b>	
5.	10:00-11:00 10:00-10:15 10:15-10:30 10:30-10:45 10:45-11:00	<b>Presentation Session II: HTA Development and Utilization</b> <ul style="list-style-type: none"> <li>➤ HTA in UHC Development in Thailand</li> <li>➤ Patient Values and Engagement in HTA – Experience of Taiwan</li> <li>➤ Transmitting the Value and Potential of HTA to Decision Makers – Malaysia</li> <li>➤ Lessons Learned from European HTA Processes</li> </ul>	Sukyeong Kim Songyot Pilasant Churn-Shiouh Gau Roza binti Sarimin  Nancy Devlin
6.	11:00-11:45	<b>Discussion Session II</b>	Sukyeong Kim
7.	11:45-12:00	<b>Closing Remarks and Group Photo</b>	Churn-Shiouh Gau Sukyeong Kim
8.	12:00-1:00	<b>Joint Lunch</b>	All

## Discussion Topics and Questions

### Discussion Session I: High-Cost Drugs and Curative Therapies

- What would be considered as a high-cost technology in your country in terms of the cost of a technology and overall annual budgetary impact of technology implementation? Would this definition differ depending on the types of technology?
- What are the key challenges in your country for providing fair pricing of and fair access to high cost technologies? What lessons can be learnt from high-income countries in managing rising drug costs? Is it reasonable and acceptable for Low and Middle Income Countries (LMICs) not to assess drugs or procedures that have been proven to be not cost-effective in developed countries?
- What novel pricing and reimbursement models should be considered for high cost therapies with curative intent? How can we achieve transparency in decision making in high-cost therapies under risk-sharing agreements?

### Discussion Session II: HTA Development and Utilization

- What factors should be considered while determining a context specific cost effectiveness threshold for LMICs? Is HTA enough for making decision in developing Universal Health Coverage (UHC) benefit packages? How can we assess the impact of HTAs on UHC development?
- What are common challenges in existing patient involvement processes? How do different stakeholders view these challenges?
- How can we incorporate patient preferences within HTA process and into reimbursement decision making? What communication methods and what topical focus areas might improve patient involvement and its impact?